TABLE 2.
Summary of T-cell and antibody responses to vaccine candidates
| Analysis | Vaccine | Response to:
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A-Gag | B-Gag | C-Gag | A-Env | B-Env | C-Env | B-pd-1 | B-pd-2 | A-Nef | B-Nef | C-Nef | ||
| Intracellular cytokine staininga | ||||||||||||
| CD4 | ABC(×4) | + | + | − | + | + | + | + | + | − | + | − |
| ABC(×6) | + | + | + | + | + | ++ | − | + | − | − | − | |
| CD8 | ABC(×4) | + | + | − | − | + | − | + | − | − | − | − |
| ABC(×6) | + | + | + | + | + | − | + | − | − | − | − | |
| ELISAb | ABC(×4) | + | + | + | ||||||||
| ABC(×6) | + | + | + | |||||||||
a
CD4+- and CD8+-T-cell responses to different vaccine candidates. When Holm-adjusted Kruskal-Wallis tests indicated overall significant differences, the data from all possible pairs of groups were compared by Wilcoxon tests with a Holm adjustment for the multiple comparisons. −, no statistically significant difference from the control (P > 0.05); +, statistically significant difference from the control only (P < 0.05); ++, statistically significant difference from both the control and all other treatment groups (P = 0.05).
b
Antibody responses to different vaccine candidates. +, the average antibody titer of the group was more than 1:1,000.